bcl-2

(redirected from Bcl-2 protein)
Also found in: Encyclopedia, Wikipedia.

BCL-2

An oncogene that inhibits apoptosis.

Bcl-2

A 25 kDa inner mitochondrial membrane protein which inhibits apoptosis, thus increasing the survival of cells (good or bad). The t(14;18) translocation results in a hybrid bcl-2/immunoglobulin heavy chain transcript consisting of the 5’ half of the bcl-2 mRNA fused to a truncated immunoglobulin heavy chain mRNA.

Normal expression
It is normally expressed by small B lymphocytes of the mantle and marginal zones and by many T cells.

Abnormal expression
Bcl-2 is over expressed in follicular lymphomas with the translocation t(14;18)(q32;q21), detected in 70 to 95% of follicular lymphomas and 20% of diffuse large B cell lymphomas. Expression is greater in grade I than in grade III follicular lymphomas.

BCL-2

An oncogene that inhibits apoptosis.

bcl-2

Proto-ONCOGENEs. This gene is over-expressed in various tumours, especially non-Hodgkin lymphoma, resulting in resistance to APOPTOSIS (programmed cell death) with encouragement of tumour growth. Antisense nucleotide sequences (oligonucleotides) targeted at BCL-2 messenger RNA reduces the expression of BCL-2 and increases apoptosis in these tumours with clinical improvement.
References in periodicals archive ?
Cells are pressured toward apoptosis by expression of pro-apoptotic BCL-2 proteins.
In addition, Bcl-2 proteins can activate any of a large family of caspase enzymes, which break down proteins and can degrade and modify various cellular components.
Expression of bcl-2 protein and transcription of the Epstein-Barr virus bcl-2 homologue BHRF-1 in Hodgkin's disease: implications for different pathogenic mechanisms.
The bcl-2 protein is a proto-oncogene that promotes oncogenesis by blocking programmed cell death (apoptosis).
Clones with high expression of Bcl-2 protein or mutant Bcl-2, termed PT67-Bcl-2 and PT67-Bcl2Y21S, were maintained for further analysis.
Pancreatic and kidney tumors also produce the Bcl-2 protein, he says, making them possible targets for this drug.
The BCL-2 protein has been reported to be important in many cancers and is the target of Genta's anticancer drug, G3139.
Several studies have shown overexpression of bcl-2 protein in a variety of solid tumors, including prostatic carcinoma (2), colorectal cancer (3), squamous cell carcinoma (SCC) [3] of the lung (4), breast cancer (5, 6), and nasopharyngeal malignancies (7).
Bcl-2 protein expression in tumor sections was examined to analyze the mechanism by which guggulsterone inhibits tumor growth.
HL-60bcl-2 cells, which are derived from a stable transfectant clone of the human bcl-2 gene into the HL-60 leukemia cell line, show 5-fold greater expression of the Bcl-2 protein compared with HL-60neo cells, a control clone transfected with vector alone.
6) More than 85% of FLs in adults demonstrate a characteristic translocation, t(14;18)(q32;q21), involving the bcl-2 gene,16 whereas most pediatric FLs are negative for bcl-2 protein and lack bcl-2/immunoglobulin heavy chain (IgH) translocations.